| 2025年12月17日 2025年12月19日に提出 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Common Stock | 処分(D) | 148,153 | 11.00 | 1,629,683 算出:株数 × 1株あたり価格。正確な値 1629683.00。 | 0 | 間接(I) See Footnote | いいえ | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月19日に提出 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) デリバティブ証券: Prefunded Warrants — 原資産 Common Stock (433,962) — 行使価格 0.0001 | 処分(D) | 433,962 | 10.999 | 4,773,148.038 算出:株数 × 1株あたり価格。正確な値 4773148.038。 | 0 | 間接(I) See Footnote | いいえ | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月19日に提出 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) デリバティブ証券: Series A Common Stock Purchase Warrants — 原資産 Common Stock (117,019) — 行使価格 8.16 | 処分(D) | 117,019 | 4.71 | 551,159.49 算出:株数 × 1株あたり価格。正確な値 551159.49。 | 0 | 間接(I) See Footnote | いいえ | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月19日に提出 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) デリバティブ証券: Series C Common Stock Purchase Warrants — 原資産 Common Stock (117,019) — 行使価格 8.16 | 処分(D) | 117,019 | 4.71 | 551,159.49 算出:株数 × 1株あたり価格。正確な値 551159.49。 | 0 | 間接(I) See Footnote | いいえ | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月19日に提出 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) デリバティブ証券: Amended Series A Common Stock Purchase Warrants — 原資産 Common Stock (158,531) — 行使価格 0.01 | 処分(D) | 158,531 | 10.99 | 1,742,255.69 算出:株数 × 1株あたり価格。正確な値 1742255.69。 | 0 | 間接(I) See Footnote | いいえ | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月19日に提出 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) デリバティブ証券: Amended Series C Common Stock Purchase Warrants — 原資産 Common Stock (250,627) — 行使価格 0.01 | 処分(D) | 250,627 | 10.99 | 2,754,390.73 算出:株数 × 1株あたり価格。正確な値 2754390.73。 | 0 | 間接(I) See Footnote | いいえ | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,218) — 行使価格 5.41 | 処分(D) | 1,218 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45 | 処分(D) | 5,833 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,218) — 行使価格 3.453 | 処分(D) | 1,218 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,479) — 行使価格 5.41 | 処分(D) | 1,479 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,750) — 行使価格 4.45 | 処分(D) | 8,750 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,291) — 行使価格 3.453 | 処分(D) | 1,291 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,187) — 行使価格 5.41 | 処分(D) | 1,187 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322641 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45 | 処分(D) | 5,833 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322641 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,187) — 行使価格 3.453 | 処分(D) | 1,187 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322641 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,250) — 行使価格 5.41 | 処分(D) | 1,250 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322638 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45 | 処分(D) | 5,833 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322638 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,250) — 行使価格 3.453 | 処分(D) | 1,250 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322638 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,218) — 行使価格 5.41 | 処分(D) | 1,218 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45 | 処分(D) | 5,833 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,187) — 行使価格 3.453 | 処分(D) | 1,187 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 5.51 | 処分(D) | 5,833 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322645 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,125) — 行使価格 3.453 | 処分(D) | 1,125 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322645 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (17,291) — 行使価格 5.27 | 処分(D) | 17,291 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322644 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (11,000) — 行使価格 4.45 | 処分(D) | 11,000 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322644 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (64,840) — 行使価格 5.27 | 処分(D) | 64,840 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322637 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (70,000) — 行使価格 4.45 | 処分(D) | 70,000 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322637 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (17,291) — 行使価格 5.27 | 処分(D) | 17,291 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322640 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (13,000) — 行使価格 4.45 | 処分(D) | 13,000 | — | — | 0 | 直接(D) | いいえ | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322640 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 5.26 | 処分(D) | 5,833 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322646 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月17日 2025年12月17日に提出 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,155) — 行使価格 3.453 | 処分(D) | 1,155 | — | — | 0 | 直接(D) | いいえ | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 提出書類を開く 0001193125-25-322646 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月16日 2025年12月17日に提出 | Hill Malcolm R Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 処分(D) | 133 | — | — | 0 | 直接(D) | いいえ | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月16日 2025年12月17日に提出 | GARNER CAM L Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 処分(D) | 2,330 | — | — | 0 | 間接(I) By Garner Investments, L.L.C. | いいえ | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月16日 2025年12月17日に提出 | Brady Todd C Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 処分(D) | 27 | — | — | 0 | 直接(D) | いいえ | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月16日 2025年12月17日に提出 | CARLSON MARILYN R. Officer: Chief Medical Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 処分(D) | 360 | — | — | 0 | 直接(D) | いいえ | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 提出書類を開く 0001193125-25-322644 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月16日 2025年12月17日に提出 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 処分(D) | 15,509 | — | — | 0 | 直接(D) | いいえ | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 提出書類を開く 0001193125-25-322637 提出書類のXMLから読み取り この行に異議を申し立てる |
| 2025年12月16日 2025年12月17日に提出 | Kowieski Mark Officer: Chief Financial Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 処分(D) | 11,815 | — | — | 0 | 直接(D) | いいえ | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 提出書類を開く 0001193125-25-322640 提出書類のXMLから読み取り この行に異議を申し立てる |